Fresenius SE & Co. KGaA (DE:FRE)
XETRA:FRE
Want to see DE:FRE full AI Analyst Report?
FRE Stock Chart & Stats
€44.62
€0.28(0.81%)
At close: 4:00 PM EST
€44.62
€0.28(0.81%)
Day’s Range― - ―
52-Week Range€35.11 - €52.96
Previous CloseN/A
Volume90.82K
Average Volume (3M)750.62K
Market Cap
€20.32B
Enterprise Value€30.27B
Total Cash (Recent Filing)€2.06B
Total Debt (Recent Filing)€11.90B
Price to Earnings (P/E)13.9
Beta0.80
Next Earnings
Aug 05, 2026EPS Estimate
0.87Next Dividend Ex-DateN/A
Dividend Yield2.05%
Share Statistics
EPS (TTM)2.66
Shares Outstanding563,237,300
10 Day Avg. Volume787,875
30 Day Avg. Volume750,621
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€54.96Price Target Upside23.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)3.55
Revenue Forecast (FY)€23.63B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryA meaningful recovery from the 2023 loss to positive net income and materially higher EBIT/net margins indicates an operational turnaround. Improved profitability tends to be durable when driven by structural cost control and mix improvements, supporting sustainable earnings, cash flow and reinvestment capacity.
Strong Free Cash FlowConsistently positive operating cash flow and a sharp FCF rebound provide durable internal funding for capex, deleveraging and distributions. Even with year-to-year volatility, materially positive FCF improves financial flexibility and reduces reliance on external financing over the medium term.
Improved LeverageA materially lower debt-to-equity ratio versus prior years reflects measurable deleveraging and stronger capitalization. This improvement enhances resilience to shocks, reduces interest burden risk, and creates room for strategic investment or further balance-sheet repair over the coming months.
Bears Say
Choppy Revenue TrendAn inconsistent multi-year revenue profile reduces visibility into top-line drivers and hinders long-term planning. Structural revenue volatility can compress margins, complicate contract negotiations and capital allocation, and means earnings and cash flows may remain less predictable over the next several quarters.
Large Absolute Debt StockEven with better ratios, a large absolute debt burden increases exposure to interest-rate and refinancing risk and limits strategic flexibility. In adverse operating or reimbursement environments, high nominal debt can constrain investment, M&A optionality and the pace of further deleveraging.
Moderate Return On EquityModest ROE levels indicate limited efficiency in converting capital into shareholder returns. Sustained moderate returns can restrict internal capital formation and may require either operational improvement or strategic shifts to generate higher long-term shareholder value relative to peers.
Fresenius SE & Co. KGaA News
FRE FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest stock price was €35.11 and its highest was €52.96 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Fresenius SE & Co. KGaA’s market cap is €20.32B.
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Aug 05, 2026 which is in 63 days.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Fresenius SE & Co. KGaA released its earnings results on May 06, 2026. The company reported €0.82 earnings per share for the quarter, missing the consensus estimate of €0.875 by -€0.055.
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA pays a Annually dividend of €1 which represents an annual dividend yield of 2.05%. See more information on Fresenius SE & Co. KGaA dividends here
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is 0.87.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Fresenius SE & Co. KGaA reported an EPS of €0.82 in its last earnings report, missing expectations of €0.875. Following the earnings report the stock price went up 1.139%.
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co. KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€54.96 (23.16% Upside)
€54.96 (23.16% Upside)
Insider Transactions
Bought Shares
Worth €794.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.67%
12-Months-Change
Fundamentals
Return on Equity
7.76%
Trailing 12-Months
Asset Growth
-1.94%
Trailing 12-Months
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
FRE Stock 12 Month Forecast
Average Price Target
€54.96
▲(23.16% Upside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius Medical Care AG & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―
Options Prices
Currently, No data available
---